JPS62273919A - 抗リウマチ剤 - Google Patents
抗リウマチ剤Info
- Publication number
- JPS62273919A JPS62273919A JP61116703A JP11670386A JPS62273919A JP S62273919 A JPS62273919 A JP S62273919A JP 61116703 A JP61116703 A JP 61116703A JP 11670386 A JP11670386 A JP 11670386A JP S62273919 A JPS62273919 A JP S62273919A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- active ingredient
- antirheumatic agent
- antirheumatic
- difucosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003435 antirheumatic agent Substances 0.000 title claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 11
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 10
- 108010074051 C-Reactive Protein Proteins 0.000 abstract description 9
- 102100032752 C-reactive protein Human genes 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 7
- 208000006820 Arthralgia Diseases 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 210000003743 erythrocyte Anatomy 0.000 abstract description 2
- 238000004062 sedimentation Methods 0.000 abstract description 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000552 rheumatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 210000001503 joint Anatomy 0.000 description 10
- 210000004247 hand Anatomy 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- 238000005299 abrasion Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 2
- 102100031621 Cysteine and glycine-rich protein 2 Human genes 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 101100092791 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-14 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003834 Triticum spelta Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001983 electron spin resonance imaging Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61116703A JPS62273919A (ja) | 1986-05-21 | 1986-05-21 | 抗リウマチ剤 |
| DE8787107352T DE3781045T2 (de) | 1986-05-21 | 1987-05-20 | Antirheumatisches arzneimittel. |
| EP87107352A EP0250831B1 (en) | 1986-05-21 | 1987-05-20 | Antirheumatic agent |
| US07/051,598 US4914085A (en) | 1986-05-21 | 1987-05-20 | Antirheumatic agent |
| ES87107352T ES2051708T3 (es) | 1986-05-21 | 1987-05-20 | Agente antirreumatico. |
| DK255487A DK255487A (da) | 1986-05-21 | 1987-05-20 | Antirheumatisk praeparat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61116703A JPS62273919A (ja) | 1986-05-21 | 1986-05-21 | 抗リウマチ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62273919A true JPS62273919A (ja) | 1987-11-28 |
| JPH0374646B2 JPH0374646B2 (enExample) | 1991-11-27 |
Family
ID=14693741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61116703A Granted JPS62273919A (ja) | 1986-05-21 | 1986-05-21 | 抗リウマチ剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4914085A (enExample) |
| EP (1) | EP0250831B1 (enExample) |
| JP (1) | JPS62273919A (enExample) |
| DE (1) | DE3781045T2 (enExample) |
| DK (1) | DK255487A (enExample) |
| ES (1) | ES2051708T3 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH024801A (ja) * | 1988-06-23 | 1990-01-09 | Rikagaku Kenkyusho | 新規なスフィンゴ糖脂質関連化合物及びその製造法 |
| US5753631A (en) * | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
| US6033663A (en) * | 1996-04-10 | 2000-03-07 | Neose Technologies, Inc. | Nucleic acids encoding GDP-Fucose pyrophosphorylase |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992017189A1 (en) * | 1991-03-29 | 1992-10-15 | The Regents Of The University Of California | Gangliosides with immunosuppressive activity |
| WO1993002686A1 (en) * | 1991-07-31 | 1993-02-18 | The Regents Of The University Of California | Gangliosides with immunosuppressive ceramide moieties |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2076418A (en) * | 1980-05-22 | 1981-12-02 | Sankyo Co | Hydrolyzed polysaccharide |
| FR2509313A1 (fr) * | 1981-07-08 | 1983-01-14 | Choay Sa | Derives de 3-fucosyl-n-acetyl lactosamine, leur preparation et leurs applications biologiques |
| DE3347522A1 (de) * | 1983-12-30 | 1985-07-11 | Troponwerke GmbH & Co KG, 5000 Köln | N-glycosylierte carbonsaeureamid-derivate als mittel bei der bekaempfung von erkrankungen des rheumatischen formenkreises |
| JPS60214737A (ja) * | 1984-04-06 | 1985-10-28 | Nippon Koutai Kenkyusho:Kk | 糖鎖関連抗原の製造法 |
-
1986
- 1986-05-21 JP JP61116703A patent/JPS62273919A/ja active Granted
-
1987
- 1987-05-20 ES ES87107352T patent/ES2051708T3/es not_active Expired - Lifetime
- 1987-05-20 US US07/051,598 patent/US4914085A/en not_active Expired - Fee Related
- 1987-05-20 EP EP87107352A patent/EP0250831B1/en not_active Expired - Lifetime
- 1987-05-20 DK DK255487A patent/DK255487A/da not_active Application Discontinuation
- 1987-05-20 DE DE8787107352T patent/DE3781045T2/de not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH024801A (ja) * | 1988-06-23 | 1990-01-09 | Rikagaku Kenkyusho | 新規なスフィンゴ糖脂質関連化合物及びその製造法 |
| US5753631A (en) * | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
| US6033663A (en) * | 1996-04-10 | 2000-03-07 | Neose Technologies, Inc. | Nucleic acids encoding GDP-Fucose pyrophosphorylase |
Also Published As
| Publication number | Publication date |
|---|---|
| DK255487A (da) | 1987-11-22 |
| EP0250831A2 (en) | 1988-01-07 |
| EP0250831B1 (en) | 1992-08-12 |
| US4914085A (en) | 1990-04-03 |
| DE3781045D1 (de) | 1992-09-17 |
| ES2051708T3 (es) | 1994-07-01 |
| DE3781045T2 (de) | 1993-03-04 |
| DK255487D0 (da) | 1987-05-20 |
| JPH0374646B2 (enExample) | 1991-11-27 |
| EP0250831A3 (en) | 1989-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koskoff et al. | Paraplegia as a complication of gout | |
| HENCH | Effect of jaundice on chronic infectious (atrophic) arthritis and on primary fibrositis: further observations; attempts to reproduce the phenomenon | |
| Osterman et al. | Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange | |
| JPS62273919A (ja) | 抗リウマチ剤 | |
| Larsson | Anaphylactic shock after ia administration of triamcinolone acetonide in a 35-year-old female | |
| Crawhall et al. | Dissolution of cystine stones during D-penicillamine treatment of a pregnant patient with cystinuria | |
| Bortz et al. | Lipoid dermato-arthritis and arthritis mutilans | |
| US4753942A (en) | Method for the treatment of inflammatory conditions | |
| Twardowski et al. | Continuous ambulatory peritoneal dialysis for psoriasis: a report of four cases | |
| KR940006324B1 (ko) | 항류머티스제 | |
| Schneider et al. | Hypervitaminosis D | |
| Steinberg et al. | Successful treatment of dermatitis due to chrysotherapy with adrenocorticotropic hormone | |
| Fuld | Use of ACTH in Agranulocytosis | |
| Aylward et al. | Treatment of rheumatoid arthritis with tolmetin: a comparison with alclofenac | |
| Nixon Jr et al. | Lipoid nodules in chronic rheumatoid arthritis nodulos lipoide in chronic arthritis rheumatoide | |
| Kehr | Comparison of intra-articular cortisone analogues in osteo-arthritis of the knee | |
| Graubard et al. | Intravenous use of procaine in the management of arthritis | |
| Maeda et al. | Plasma exchange for treatment of intractable psoriasis | |
| RU1638852C (ru) | Способ лечения атопического дерматита | |
| Kalz et al. | The External Use of Sulfonamides in Dermatology | |
| RU1827260C (ru) | Способ лечени рассе нного склероза | |
| ZARAFONETIS et al. | Treatment of rheumatoid arthritis with p-aminobenzoate and acetylsalicylic acid | |
| Hanzlik | Pharmacology of Bismuth compounds in treatment of syphilis: a summary | |
| McCANN | Parathyroid therapy | |
| Pollock | Calcinosis universalis |